PRFX (39) SBFM (44) APVO (46) SILO (19) ⌘ Pro Terminal →

HCW Biologics Inc. (HCWB) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell HCWB stock right now?

HCW Biologics Inc. (HCWB) currently earns a Roarable Rating of E (Strong Sell — SELL) with 27/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is HCWB's 12-month price target and RQD AI Jury consensus?

HCWB's 12-month base price target is $1.02 (range $0.8 to $25.14), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.18 -3.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

HCW Biologics Inc. (HCWB) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCWB)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMOVERSOLD (<32)

31.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.18H: $24

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on HCWB

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 20.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (30)

10/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like HCWB

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCWB)

✓Walkthrough of HCWB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HCWB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.30%⚡ TESTING RESISTANCE

2026-10-30O $1.16H $1.19L $1.10C $1.18VOL 34.5K

RES: $2.33SUP: $0.98SMA50: $1.92SMA200: $4.12

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HCWB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HCWB Butterfly Map → + Track HCWB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HCWB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HCWB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HCWB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCWB)

Health Care Rank #982 of 1016 ⚔️ PRFX vs HCWB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HCWB vs. PRFX, SBFM, APVO, SILO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, HCW Biologics Inc. (HCWB) ranks #982 by composite RQD confidence (27/100, grade E) and #983 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, HCWB leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with HCWB at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HCWB ACTIVE HCW Biologics Inc.	E	27/100	—	20.0%	-35.0%	-3.28%	$2.6M	Benchmark Subject
PRFX PRF Technologies Ltd.	D-	39/100	—	-30.0%	-35.0%	-3.86%	$2.6M	/prfx-vs-hcwb →
SBFM Sunshine Biopharma Inc.	D	44/100	—	33.8%	-21.4%	+7.07%	$2.5M	/sbfm-vs-hcwb →
APVO Aptevo Therapeutics Inc.	D	46/100	—	—	-35.0%	+4.62%	$2.5M	/apvo-vs-hcwb →
SILO Silo Pharma Inc.	E	19/100	—	38.6%	-35.0%	-6.72%	$2.4M	/silo-vs-hcwb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001828673

In its most recent audited fiscal period (FY2025, filed 2025-12-31), HCW Biologics Inc. (HCWB) reported GAAP revenue of $54.2K (-97.9% vs. FY2024 revenue of $2.6M ) , GAAP net income of -$8.0M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (+7.6% YoY). On the balance sheet, HCWB closed FY2025 with $24.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$54.2K	-$8.0M	-$13.4M	-$13.4M	$24.5M	—
FY2024 (FY)	2024-12-31	$2.6M	-$30.0M	-$14.2M	-$14.5M	$30.2M	—
FY2023 (FY)	2023-12-31	$0	-$25.0M	-$22.5M	-$22.5M	—	—

3. HCWB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HCWB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, HCW Biologics Inc. (NASDAQ: HCWB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.18 (-3.28% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HCWB ranks #982 in composite RQD confidence.

How does HCWB compare to PRFX and SBFM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCWB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 20.0%, and ROIC of -35.0%. By comparison, PRFX (PRF Technologies Ltd.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, HCWB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HCWB?

Per HCWB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001828673), HCW Biologics Inc. generated $54.2K in revenue (-97.9% YoY), -$8.0M in net income, and -$13.4M in free cash flow against $24.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HCWB trading relative to its 50-day, 200-day, and 52-week technical levels?

HCWB last traded at $1.18 (-3.28% on volume of 33,448 shares), positioning the stock -38.54% below its 50-day simple moving average ($1.92) and -71.36% below its 200-day simple moving average ($4.12). Across its 52-week range of $1.09 to $23.94, HCWB sits at the 0.4% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.03 to $1.33).

HCWB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell HCWB stock right now?

HCW Biologics Inc. (HCWB) currently earns a Roarable Rating of E (Strong Sell — SELL) with 27/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is HCWB's 12-month price target and RQD AI Jury consensus?

HCWB's 12-month base price target is $1.02 (range $0.8 to $25.14), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: HCWB RQD Cockpit HCWB 12M Forecast HCWB Earnings & Move HCWB Dividends & DRIP HCWB Insiders & 13F HCWB Whale Options HCWB Profit Sankey HCWB News & Why